# Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors

> **NCT00003198** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** ifosfamide
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00003198
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-11
- **Primary completion:** 2000-05
- **Final completion:** 2000-05
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003198, "Ifosfamide and Topotecan in Treating Patients With Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00003198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*